Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Proteome Sciences ( (GB:PRM) ) just unveiled an update.
Proteome Sciences has launched a UK-only retail share offer of up to 3,428,571 new ordinary shares at 1.75 pence per share, aiming to raise up to £60,000 from existing retail shareholders via the BookBuild platform, in parallel with a separate placing and subscription already completed at the same issue price. The proceeds from this combined equity raise will be directed towards expanding and upgrading the company’s proteomics technology suite—boosting TMT plexing from 32X to 96X, launching a new DXT isotopic tag range, introducing ‘Solvent Shift’ chemoproteomic workflows, concluding a DXT licence, and increasing staff and mass spectrometry capacity in San Diego—moves that are intended to support growing demand, enhance its technical offering and strengthen its competitive position in high-throughput proteomics, while also reinforcing engagement with its retail investor base.
The most recent analyst rating on (GB:PRM) stock is a Buy with a £3.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.
Spark’s Take on GB:PRM Stock
According to Spark, TipRanks’ AI Analyst, GB:PRM is a Neutral.
The score is primarily held down by very weak financial fundamentals (negative profitability, negative equity, and negative operating/free cash flow). Technicals are supportive with price above key moving averages and positive MACD, but the elevated RSI signals overbought risk. Valuation is constrained by a negative P/E and no dividend yield data.
To see Spark’s full report on GB:PRM stock, click here.
More about Proteome Sciences
Proteome Sciences PLC, listed on AIM under the ticker PRM, operates in the proteomics and mass spectrometry-based biomarker and analytical services industry. The company focuses on advanced mass tag technologies, including Tandem Mass Tag (TMT) and DXT isotopic tags, and chemoproteomic workflows, serving pharmaceutical, biotech and research customers, with growing operational capacity in markets such as San Diego to meet rising demand for high-throughput proteomic analysis.
Average Trading Volume: 256,067
Technical Sentiment Signal: Buy
Current Market Cap: £9.53M
For an in-depth examination of PRM stock, go to TipRanks’ Overview page.